In our study, we observed a statistically significant reduction in inflammatory markers (CRP: p = 0.047) and BMI (p = 0.037) in PAD patients with clinical improvement at the 6-month follow-up, which supports the data from the literature. This evidence concerns the gene CRP and peripheral arterial disease.